Determining if your HUB should be insourced, outsourced, or a hybrid of those two options is a big decision. And finding the right answer can determine the future success of your patient access program.
Archbow's experience with program migrations has taught us what to anticipate, how to formulate realistic expectations, and where to find the right fit for teams needing a change. Q&A with Anna Beth Lindenmeyer
The entrance of cell and gene therapies into the market is impacting every corner of the industry. Likewise, the demand for high-quality CGT consulting services continues to grow with each passing day.